Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
about
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineGenomic profiling in luminal breast cancerQuantification of HER family receptors in breast cancerHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer paAnalytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimensClinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomesMolecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancerPAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression.Defining breast cancer intrinsic subtypes by quantitative receptor expression.Development and verification of the PAM50-based Prosigna breast cancer gene signature assayThe Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes.Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New.Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer.Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells.Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.Gene signatures in breast cancer: current and future uses.The genomic landscape of breast cancer as a therapeutic roadmapPrognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamidePrognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyThe management of early-stage and metastatic triple-negative breast cancer: a review.Estrogen receptor α regulates ATM Expression through miRNAs in breast cancerMultigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.Advances in the approach to novel drug clinical development for breast cancer.Optimal adjuvant chemotherapy in breast cancer: selection of agents.Biomarker assessment and molecular testing for prognostication in breast cancer.NanoString, a novel digital color-coded barcode technology: current and future applications in molecular diagnostics.Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial.A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures.Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
P2860
Q26853619-C958434F-7952-4F61-B53A-5CE567F1B6A4Q26862681-1773BACA-6E03-44E0-92E4-C6D3F53CD7ECQ27015506-C693C97E-3EDE-4D68-9C78-713010888B8BQ28077637-B4D0D8A0-B2C0-4B68-BCDC-760ABE392023Q30543788-64DF1FFD-28FB-4BDD-9E71-5E8BBC15676FQ31160308-6D3BC52A-A9D5-4C3A-9574-4439B652A349Q33559365-664CF976-C194-47E6-BDCD-4E592E0DBE53Q33827057-2C41B9DC-3983-4FD6-8672-2DC3D64F9C8DQ33834198-F9B328F8-2A4D-434C-92CF-9111060A1E87Q33883406-2D9BA420-23AD-4D5A-9466-9FCE8330068AQ33927000-A1DC2AC2-4235-4AC1-95B2-D6C3A46FEE65Q34120668-FF49EEB9-6927-4BCC-9371-D5D44D455C7FQ34433549-213C3F09-51D5-472E-9845-BF78E672F9E5Q35419840-9FAD2A23-F08E-4945-AC6D-261EEDA38F80Q35492620-746F16CF-734C-4D46-8E33-993A779AD021Q35586697-0EAE6523-04A1-42DF-952D-4C3E8DE31768Q35752868-61EA1745-E522-4198-869B-A7AC4682BD86Q35962877-B69D1480-AE6B-4E70-96F5-51571BCB80EFQ36055133-C354BED3-96F7-4231-94C5-CB1F1BB70454Q36145737-28740FBF-67A2-4352-A186-B87E32B3705CQ36299754-758036A7-45B6-4393-B755-6C0AA338EA1BQ36383626-7AD0E3E9-3EAF-4FFC-92D9-3BD65F28638DQ36525765-071B7AE4-90D5-4606-898A-595CA70C8657Q36558069-3151442C-C6A9-45F8-AE5F-B6EFC646D3F6Q36640848-BC17C7CB-B33E-4806-972B-3216E350E213Q36678505-93E6C983-43F9-4C54-912A-02257783F182Q37080240-3FA7A761-4960-44B0-8AE9-E446FBC385BAQ37185232-BC487008-D9BB-4252-9D24-6BE79E48222FQ37383276-78A3CE12-1331-45CA-9F78-4A2F8CF0289CQ37618855-5F107644-035E-40FB-AFDC-27091157265AQ38061108-825E3DD1-A7D6-4640-913A-30CCE36B52CEQ38206546-8465C35C-0AFD-40E0-ACDF-567F05FEA110Q38235713-FAAABB36-94FE-4A5F-965B-6EDA8A07C553Q38696790-CE8A7F37-9293-4E1A-BCCE-9158749AD9E8Q38787248-28BC78D6-6454-4452-85CD-E5AD1845D1A9Q38853194-550CA537-1C7D-4418-95B4-15BB1C2E9F78Q42435532-558B98BD-B19B-4951-83DF-E6BB9FA4EA1BQ42438922-65743BDB-10CA-4C8D-B5BB-A712C59B5EC2Q42454757-D8B8C958-C9EF-4A91-875E-51B6F3C04CB5Q42470916-508346C2-8A2F-4E62-A1FC-360D7E01F7FC
P2860
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 February 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Responsiveness of intrinsic su ...... CIC.CTG MA.5 randomized trial.
@en
Responsiveness of intrinsic su ...... CIC.CTG MA.5 randomized trial.
@nl
type
label
Responsiveness of intrinsic su ...... CIC.CTG MA.5 randomized trial.
@en
Responsiveness of intrinsic su ...... CIC.CTG MA.5 randomized trial.
@nl
prefLabel
Responsiveness of intrinsic su ...... CIC.CTG MA.5 randomized trial.
@en
Responsiveness of intrinsic su ...... CIC.CTG MA.5 randomized trial.
@nl
P2093
P2860
P50
P1476
Responsiveness of intrinsic su ...... NCIC.CTG MA.5 randomized trial
@en
P2093
Carole Davis
Dongsheng Tu
Inge J Stijleman
Joel S Parker
K David Voduc
Kathleen I Pritchard
Lois E Shepherd
Mark N Levine
Matthew J Ellis
Philip S Bernard
P2860
P304
P356
10.1158/1078-0432.CCR-11-2956
P407
P577
2012-02-20T00:00:00Z